XML 41 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Contract Balances (Details) - USD ($)
3 Months Ended
Jan. 02, 2018
Mar. 31, 2018
Mar. 31, 2017
Changes in the Company’s contract assets and contract liabilities      
Contract asset, Additions   $ 4,041,000  
Contract asset, Balance at End of Period   4,041,000  
Contract liabilities:      
Deferred revenue, Deductions   (7,834,000)  
Deferred revenue, Balance at End of Period $ 89,967,000 82,133,000  
Revenues recognized from changes in contract balances      
Revenue recognized   11,540,000  
Performance obligations satisfied in previous periods $ 4,600,000    
Deferred revenue, reduction   11,875,000 $ 12,811,000
Technological Improvements      
Revenues recognized from changes in contract balances      
Revenue recognized   101,000  
Takeda      
Revenues recognized from changes in contract balances      
Revenue recognized   10,900,000  
Deferred revenue, reduction   6,900,000  
Debiopharm      
Revenues recognized from changes in contract balances      
Revenue recognized   500,000  
CytomX | Milestone related      
Revenues recognized from changes in contract balances      
Revenue from contract with customer     6,000,000
CytomX | Technological Improvements      
Revenues recognized from changes in contract balances      
Revenue from contract with customer     80,000
CytomX | License Revenue [Member]      
Revenues recognized from changes in contract balances      
Revenue from contract with customer     12,700,000
Upon shipment      
Revenues recognized from changes in contract balances      
Revenue from contract with customer   335,000  
Upon shipment | CytomX      
Revenues recognized from changes in contract balances      
Revenue from contract with customer     $ 703,000
ASU 2014-09      
Revenues recognized from changes in contract balances      
Deferred revenue, reduction   1,000,000  
Contract asset recorded for a probable milestone   $ 5,000,000